Efficacy of PDT for different types of cancer.
| Cancer | Photosensitizer | Response | Cure rate | Publication |
|---|---|---|---|---|
| CIN | Photofrin | 96.6% (127/131) | 96.6% | Muroya21 |
| 5-ALA | 42% (3/7) 51% (16/31) 75% (9/12) 95% (19/20) | 42% (3/7) 31% (10/31) 33% (4/12) | Hillemanns23 Keefe24 Barnett25 Wierrani26 | |
| 91% (10/11) | Borner27 | |||
| 80% (4/5) | 80% | Wang29 | ||
| HAL | 63% (15/24) | 63% | Soergel33 | |
| VIN | 5-ALA | 89% 83% | 10% (1/10) 16% (1/6) | Martin-Hirsh40 Kurwa41 |
| 64% | 52% (13/25) | Hillemanns42 | ||
| mTHPC | 66% (4/6) | Cambell44 | ||
| Ovarian | Photofrin | 15% (2/13) | Wilson56 | |
| Chest wall breast cancer recurrences | Photofrin II Photofrin mTHPC | 64% (24/37) 100% (14/14) 100% (7/7) | 13.5% (15/37) 64% (9/14) | Khan77 Cuenca76 Wyss78 |
| Npe6 | 75% (3/4) | 50% (2/4) | Taber75 |
Response means complete ablation or decrease of lesion site. Cure rate means no recurrence of the disease was noted at follow up of 6 months or longer.